Interpretability of the Quantra viscoelastic test in patients with haematological malignancies presenting severe thrombocytopenia
Adrien Contejean, Florence Blanc-Jouvan, Noémie Zucman, Claire Reynes, Yacine Haddad, Cloe Derray, Constance Moulinier, Natacha Mauz, Nicolas Daguindau, Marion Chevalier, Stéphanie Tardy, Frédérique Orsini-Piocelle, Anne Parry, Hannah Moatti, Albrice Levrat, Tristan Delory
Viscoelastic tests have been scarcely evaluated in patients with haematological malignancies and severe thrombocytopenia. The VISCOTHEM-1 study investigated the interpretability of Quantra results in these patients, with platelet count less than 50 × 10
9
/l. The objective was to evaluate the correlation between clot stiffness and platelet contribution to clot stiffness (PCS) measured by Quantra and conventional laboratory platelet counts. In this exploratory, single-centre, nonrandomized prospective cohort (June–December 2024), adults with haematological malignancies, platelet count less than 50 × 10
9
/l and no antiplatelet/anticoagulant therapy or platelet-function disorders were enrolled. Patients underwent a blood count, coagulation assays, Quantra and ROTEM assessments. For patients who received transfusion, a second draw was performed one hour posttransfusion. Forty-six patients were included: 16 with platelet counts less than 10 × 10
9
/l, 15 between 10 and 19 × 10
9
/l, and 15 between 20 and 49 × 10
9
/l. Fourteen patients (31%) experienced bleeding. The median PCS measured by Quantra was 2 hPa [interquartile range (IQR) 2–3.38] and correlated strongly with platelet count using conventional assay (